ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 9.01B 7.82B 7.32B 6.7B 12.62B 857B 12.81B 85.61B 33.6B 429B 33.81B 33.08B 1,427B | P/E 2026 * |
-15.2x | P/E 2027 * | -29.5x |
|---|---|---|---|---|---|
| Enterprise Value | 8.61B 7.47B 6.99B 6.4B 12.07B 819B 12.25B 81.85B 32.12B 410B 32.32B 31.62B 1,364B | EV / Sales 2026 * |
9.35x | EV / Sales 2027 * | 6.25x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 30/06/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 30/04/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 12/12/2005 |
| Director/Board Member | 73 | 30/04/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 24/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 9.01B | |
| +0.93% | -1.43% | +1.61% | +14.93% | 48.57B | |
| +0.26% | +9.34% | +415.26% | +533.80% | 41.95B | |
| -1.53% | -6.11% | +26.37% | +7.15% | 38.85B | |
| +0.69% | +0.79% | +7.35% | +63.05% | 37.24B | |
| +2.47% | +8.33% | +15.16% | +48.37% | 30.67B | |
| -0.47% | +0.01% | +34.08% | +126.09% | 16.41B | |
| +2.31% | -0.87% | - | - | 16.1B | |
| +0.29% | +1.81% | +4.92% | +18.60% | 13.97B | |
| -1.43% | -9.55% | -2.90% | -36.38% | 12.62B | |
| Average | +0.48% | -0.30% | +62.73% | +96.95% | 28.48B | |
| Weighted average by Cap. | +0.47% | +0.39% | +82.62% | +121.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 921M 799M 748M 685M 1.29B 87.58B 1.31B 8.75B 3.44B 43.86B 3.46B 3.38B 146B | 1.4B 1.22B 1.14B 1.04B 1.96B 133B 1.99B 13.32B 5.23B 66.75B 5.26B 5.15B 222B |
| Net income | -590M -512M -479M -439M -827M -56.12B -839M -5.61B -2.2B -28.1B -2.21B -2.17B -93.5B | -319M -277M -259M -237M -447M -30.32B -453M -3.03B -1.19B -15.18B -1.2B -1.17B -50.51B |
| Net Debt | -396M -343M -321M -294M -554M -37.62B -563M -3.76B -1.48B -18.84B -1.49B -1.45B -62.69B | -241M -209M -196M -179M -337M -22.89B -342M -2.29B -898M -11.46B -904M -884M -38.14B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
